Stefan Müllner
Microbiology
Biotechnology and Microbiology
Philippines
Biography
Stefan Müllner, a chemist by training, did his Ph.D. thesis in protein biochemistry and postdoc in molecular biology. During his long time as CEO of Protagen AG, he grew the company into the global technology leader in blood based patient stratification to enable novel autoimmune therapy. Before he co-founded Protagen, he worked as Head of Enzyme Technology at Henkel, as well as preclinical pharma research and corporate research at Hoechst, now Sanofi. Stefan has a very broad background and in-depth experience in investments in biotech from his engagements in venture capital and corporate venture capital. He is author and co-author of 48 peer reviewed publications and inventor on 60 patents.
Research Interest
Industrial application of biotechnology, microbiology and recombinant technologies; Industrial production and application of enzymes; Biocatalysis; Biotransformation; Metagenome screening; Platform technologies for enzyme screening and performance selection; Synergies between chemistry with renewable resources, biotechnology and microbiology; Bioeconomy; Enzyme purification, stabilization, formulation; Microbiology screening for novel chemical entities, pharmaceutical leads, and bioactive ingredients
